Sugi Predict

Sugi Predict / Compounds / SCHEMBL2420122

SCHEMBL2420122

SCHEMBL2420122

COC(=O)C(Cc1ccc(O)cc1)NC(=O)OCc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.67
▸ ALOX15 P16050 1/20 0.67
▸ CTSL P07711 3/20 0.65
▸ CTSB P07858 3/20 0.65
▸ CTSS P25774 3/20 0.65
▸ CTSK P43235 3/20 0.65
▸ TSHR P16473 4/20 0.62
▸ MDM4 O15151 1/20 0.62
▸ MDM2 Q00987 1/20 0.62
▸ CYP3A4 P08684 3/20 0.60
▸ MEN1 O00255 1/20 0.60
▸ MAPT P10636 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ TACR1 P25103 2/20 0.60
▸ KYNU Q16719 1/20 0.59
▸ ATM Q13315 1/20 0.58
▸ TRPM8 Q7Z2W7 1/20 0.57
▸ THRB P10828 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7294741 1.00 ALDH1A1 (0.67) ALDH1A1ALOX15CTSLCTSBCTSS
SCHEMBL2402461 1.00 ALDH1A1 (0.67) ALDH1A1ALOX15CTSLCTSBCTSS
SCHEMBL7151822 0.94 ALDH1A1 (0.74) ALDH1A1ALOX15CTSLCTSBCTSS
SCHEMBL329686 0.94 ALDH1A1 (0.74) ALDH1A1ALOX15CTSLCTSBCTSS
SCHEMBL7274447 0.94 ALDH1A1 (0.61) ALDH1A1ALOX15CTSLCTSBCTSS
Hydrochloric Acid SCHEMBL7928050 0.93 ALDH1A1 (0.72) ALDH1A1ALOX15CTSLCTSBCTSS
SCHEMBL5399986 0.92 ALDH1A1 (0.67) ALDH1A1ALOX15CTSLCTSBCTSS
SCHEMBL3065366 0.92 CTSL (0.64) ALDH1A1ALOX15CTSLCTSBCTSS
SCHEMBL30343691 0.92 CTSL (0.64) ALDH1A1ALOX15CTSLCTSBCTSS
SCHEMBL11658292 0.92 ALDH1A1 (0.61) ALDH1A1ALOX15CTSLCTSBCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109724-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2026-04-23 — — US disclosed
EP-4107164-B1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2025-12-03 — — EP disclosed
US-12264173-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2025-04-01 — — US disclosed
US-20240174704-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2024-05-30 — — US disclosed
US-11767337-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2023-09-26 — — US disclosed
US-20230295201-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2023-09-21 — — US disclosed
EP-4106877-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-12-28 — — EP disclosed
EP-4107164-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-12-28 — — EP disclosed
US-20220356196-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2022-11-10 — — US disclosed
US-20210284670-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2021-09-16 — — US disclosed
US-5750754-A TERTIARY BUTYL 3-METHYL-4-SUBSTITUTED BUTYRATE; CHEMICAL INTERMEDIATES FOR ANTICAOGULANT DRUGS ZENECA LIMITED (GB) 1998-05-12 — — US disclosed
US-5733522-A USEFUL FOR NMR DIAGNOSIS AND DIAGNOSTIC RADIOLOGY; FOR CONTRASTING THE HEPATOBILIARY SYSTEM SCHERING AKTIENGESELLSCHAFT (DE) 1998-03-31 — — US disclosed
US-5654467-A Process for the production of C-substituted diethylenetriamines SCHERING AKTIENGESELLSCHAFT (DE) 1997-08-05 — — US disclosed
US-5563141-A INHIBIT CELL ADHESION FOR EXAMPLE, PLATELET AGGRE GATION ZENECA LIMITED (GB) 1996-10-08 — — US disclosed
EP-0690847-A1 HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1996-01-10 — — EP disclosed
CN-1100411-A Preparation of C-substituted diethylentriamine SCHERING AG (DE) 1995-03-22 — — CN disclosed
WO-1994022835-A2 HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1994-10-13 — — WO disclosed
EP-0202606-B1 IMMOBILIZED ENZYME HAVING REVERSIBLE SOLUBILITY TANABE SEIYAKU CO., LTD. (JP) 1991-03-27 — — EP disclosed
US-4783409-A Immobilized enzyme having reversible solubility TANABE SEIYAKU CO., LTD. (JP) 1988-11-08 — — US disclosed
EP-0202606-A2 Immobilized enzyme having reversible solubility TANABE SEIYAKU CO., LTD. (JP) 1986-11-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295201-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 ALDH1A1 1459/4885ALOX15 165/4885CTSL 760/4885
US-20220356196-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 ALDH1A1 1459/4885ALOX15 165/4885CTSL 760/4885
US-20260109724-A1 ANTIVIRAL COMPOUNDS IRF3, IFNAR1, HAVCR2 ALDH1A1 744/4885ALOX15 1538/4885CTSL 2167/4885
US-20210284670-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 ALDH1A1 1459/4885ALOX15 165/4885CTSL 760/4885
US-12264173-B2 Antiviral compounds MAVS, HAVCR2, ZC3HAV1 ALDH1A1 1459/4885ALOX15 165/4885CTSL 760/4885
US-11767337-B2 Antiviral compounds MAVS, HAVCR2, ZC3HAV1 ALDH1A1 1459/4885ALOX15 165/4885CTSL 760/4885
US-20240174704-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 ALDH1A1 1459/4885ALOX15 165/4885CTSL 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.